Pharminent

FDA clears the first “radioligand equivalent”

Curium’s Bexlutry is the first product approved under the new designation — an equivalent to Novartis’s Lutathera, both lutetium Lu 177 dotatate, opening generic-style competition in a modality long insulated by isotope supply and manufacturing complexity rather than patent.

Novartis drops lifonebart in ALS, keeps it in Alzheimer’s

The TREM2 stabiliser missed both primary and secondary endpoints in the 251-patient Phase 2 Astrals trial; the molecule continues in Novartis’s ongoing Alzheimer’s study.

Novartis pays $125M for a way across the blood-brain barrier

Novartis exercised its option on Sironax’s large-molecule delivery platform, paying $125 million on closing under an agreement worth up to $175 million in total upfront and near-term payments.

Lilly licenses nervous-system delivery from QurCan

Eli Lilly licensed QurCan’s polymer platform for non-viral delivery of mRNA, DNA and oligonucleotide payloads to the nervous system — up to $237 million in milestones per programme plus an undisclosed upfront and an equity investment.

Sling raises $123M for a thyroid eye disease pill

A Series C led by Forbion funds Phase 3 (ORBIT) of linsitinib, an oral IGF-1R inhibitor for thyroid eye disease, with initial data expected in mid-2028.